{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:40:26Z","timestamp":1784698826183,"version":"3.55.0"},"reference-count":63,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Asthma is a common respiratory disease, which may be associated with an increased risk of herpes zoster (HZ), often a debilitating disease associated with severe pain. This is the first systematic review with the objective of summarising evidence on HZ burden in adults with asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A global systematic literature review and meta-analysis was conducted (MEDLINE and Embase, 2003\u20132024) on HZ burden (incidence, risk and complications) in adults (\u226518\u2005years) with asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 19 studies included on HZ outcomes in adults with asthma. Pooled HZ incidence per 1000 person-years was 5.71 (95% CI 4.68\u20136.96) in adults aged \u226518\u2005years (4.20 (95% CI 3.09\u20135.70) in those aged &lt;60\u2005years<jats:italic>versus<\/jats:italic>10.33 (95% CI 9.17\u201311.64) in those aged \u226560\u2005years). The pooled rate ratio for developing HZ was 1.23 (95% CI 1.11\u20131.35) in those aged \u226518\u2005years and 1.36 (95% CI 1.15\u20131.61) in those aged \u226550\u2005years. The risk of HZ was higher in people with asthma using systemic corticosteroids, long-acting \u03b2-agonists plus inhaled corticosteroids and \u201cadd-on therapy\u201d. Asthma was also associated with an increased risk of post-herpetic neuralgia (OR 1.21, 95% CI 1.06\u20131.37) and HZ ophthalmicus (OR 1.9, 95% CI 1.1\u20133.2). Differences in study design, setting, case definitions and follow-up durations led to heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This systematic literature review and meta-analysis found that adults with asthma have an increased risk of HZ, with higher risks in older age groups and in those on certain treatments, such as oral corticosteroids. HZ vaccines are available for adults, including those with comorbidities such as asthma, and can be considered as part of integrated respiratory care.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00462-2024","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:55:16Z","timestamp":1718895316000},"page":"2400462","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis"],"prefix":"10.1183","volume":"64","author":[{"given":"Kevin J.","family":"Mortimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro A.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid T.","family":"Sep\u00falveda-Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Jorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Vroling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-3675","authenticated-orcid":false,"given":"Charles","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"2024102103310565000_64.2.2400462.1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa005"},{"key":"2024102103310565000_64.2.2400462.2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28620"},{"key":"2024102103310565000_64.2.2400462.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.05.021"},{"key":"2024102103310565000_64.2.2400462.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00785-1"},{"key":"2024102103310565000_64.2.2400462.5","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2023. Available from: https:\/\/ginasthma.org\/"},{"key":"2024102103310565000_64.2.2400462.6","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1002\/iid3.718","article-title":"Association of asthma and herpes zoster, the role of vaccination: a literature review","volume":"10","author":"Shrestha","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"2024102103310565000_64.2.2400462.7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12931-022-02305-1","article-title":"Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?","volume":"24","author":"Safonova","year":"2023","journal-title":"Respir Res"},{"key":"2024102103310565000_64.2.2400462.8","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol Infect"},{"key":"2024102103310565000_64.2.2400462.9","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800106"},{"key":"2024102103310565000_64.2.2400462.10","doi-asserted-by":"crossref","first-page":"25151355221084535","DOI":"10.1177\/25151355221084535","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"2024102103310565000_64.2.2400462.11","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37"},{"key":"2024102103310565000_64.2.2400462.12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40121-021-00581-w","article-title":"A cross-sectional concept elicitation study to understand the impact of herpes zoster on patients\u2019 health-related quality of life","volume":"11","author":"Van Oorschot","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2024102103310565000_64.2.2400462.13","doi-asserted-by":"publisher","DOI":"10.3390\/v14020192"},{"key":"2024102103310565000_64.2.2400462.14","doi-asserted-by":"crossref","unstructured":"Somayaji R , Elliott JA , Sibbald RG . Dermatologic manifestations of herpes zoster. In: Watson CPN , Gershon AA , Oxman MN , eds. Herpes Zoster: Postherpetic Neuralgia and Other Complications. Focus on Treatment and Prevention. Cham, Springer, 2017; pp. 103\u2013115.","DOI":"10.1007\/978-3-319-44348-5_10"},{"key":"2024102103310565000_64.2.2400462.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"2024102103310565000_64.2.2400462.16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.vaccine.2018.11.079","article-title":"Costs of herpes zoster complications in older adults: a cohort study of US claims database","volume":"37","author":"Meyers","year":"2019","journal-title":"Vaccine"},{"key":"2024102103310565000_64.2.2400462.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181565"},{"key":"2024102103310565000_64.2.2400462.18","doi-asserted-by":"crossref","first-page":"e0255877","DOI":"10.1371\/journal.pone.0255877","article-title":"Herpes zoster epidemiology in Latin America: a systematic review and meta-analysis","volume":"16","author":"Bardach","year":"2021","journal-title":"PLoS One"},{"key":"2024102103310565000_64.2.2400462.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1514-y"},{"key":"2024102103310565000_64.2.2400462.20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1847582"},{"key":"2024102103310565000_64.2.2400462.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.009"},{"key":"2024102103310565000_64.2.2400462.22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","article-title":"Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns","volume":"52","author":"Steinmann","year":"2024","journal-title":"Infection"},{"key":"2024102103310565000_64.2.2400462.23","unstructured":"Higgins JPT , Thomas J , Chandler J , et al. , eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). 2023. https:\/\/training.cochrane.org\/handbook Date last accessed: 21 June 2024 ."},{"key":"2024102103310565000_64.2.2400462.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2024102103310565000_64.2.2400462.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2024102103310565000_64.2.2400462.26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/22.6.1189"},{"key":"2024102103310565000_64.2.2400462.27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa167"},{"key":"2024102103310565000_64.2.2400462.28","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn217"},{"key":"2024102103310565000_64.2.2400462.29","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys147"},{"key":"2024102103310565000_64.2.2400462.30","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.167092"},{"key":"2024102103310565000_64.2.2400462.31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"key":"2024102103310565000_64.2.2400462.32","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.jvacx.2019.100007","article-title":"Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England","volume":"1","author":"Bollaerts","year":"2019","journal-title":"Vaccine X"},{"key":"2024102103310565000_64.2.2400462.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911"},{"key":"2024102103310565000_64.2.2400462.34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"key":"2024102103310565000_64.2.2400462.35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.arbres.2023.08.010","article-title":"Chronic respiratory diseases as a risk factor for herpes zoster infection","volume":"59","author":"Morena","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"2024102103310565000_64.2.2400462.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.08.016"},{"key":"2024102103310565000_64.2.2400462.37","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1016\/j.vaccine.2017.08.065","article-title":"Prevaccination epidemiology of herpes zoster in Denmark: quantification of occurrence and risk factors","volume":"35","author":"Schmidt","year":"2017","journal-title":"Vaccine"},{"key":"2024102103310565000_64.2.2400462.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053133"},{"key":"2024102103310565000_64.2.2400462.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.06.020"},{"key":"2024102103310565000_64.2.2400462.40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s13555-021-00535-7","article-title":"Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007\u20132018","volume":"11","author":"Batram","year":"2021","journal-title":"Dermatol Ther"},{"key":"2024102103310565000_64.2.2400462.41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40121-023-00902-1","article-title":"Incidence and burden of herpes zoster in Sweden: a regional population-based register study","volume":"13","author":"Sodergren","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2024102103310565000_64.2.2400462.42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-018-0268-8","article-title":"Burden of herpes zoster in the Japanese population with immunocompromised\/chronic disease conditions: results from a cohort study claims database from 2005\u20132014","volume":"9","author":"Imafuku","year":"2019","journal-title":"Dermatol Ther"},{"key":"2024102103310565000_64.2.2400462.43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/1346-8138.15214","article-title":"Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014","volume":"47","author":"Imafuku","year":"2020","journal-title":"J Dermatol"},{"key":"2024102103310565000_64.2.2400462.44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-020-00453-x","article-title":"Asthma increases the risk of herpes zoster: a nested case-control study using a national sample cohort","volume":"16","author":"Kim","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024102103310565000_64.2.2400462.45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/02770903.2016.1211142","article-title":"Adult asthma is associated with an increased risk of herpes zoster: a population-based cohort study","volume":"54","author":"Peng","year":"2017","journal-title":"J Asthma"},{"key":"2024102103310565000_64.2.2400462.46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2013.6277","article-title":"Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study","volume":"132","author":"Borkar","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2024102103310565000_64.2.2400462.47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","article-title":"Asthma as a risk factor for zoster in adults: a population-based case-control study","volume":"137","author":"Kwon","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103310565000_64.2.2400462.48","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268814003653"},{"key":"2024102103310565000_64.2.2400462.49","doi-asserted-by":"crossref","first-page":"e0298526","DOI":"10.1371\/journal.pone.0298526","article-title":"Do statistical heterogeneity methods impact the results of meta-analyses? A meta epidemiological study","volume":"19","author":"Mheissen","year":"2024","journal-title":"PLoS One"},{"key":"2024102103310565000_64.2.2400462.50","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.mayocp.2021.05.029","article-title":"Corticosteroid use and risk of herpes zoster in a population-based cohort","volume":"96","author":"Qian","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024102103310565000_64.2.2400462.51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1440-1592.2004.00351.x","article-title":"Dose\u2013response relationship for inhaled corticosteroids and the add-on effect of long-acting \u03b22-adrenergic receptor agonists in adult chronic asthmatics","volume":"53","author":"Hojo","year":"2004","journal-title":"Allergol Int"},{"key":"2024102103310565000_64.2.2400462.52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/07853890.2017.1309060","article-title":"Asthma status is an independent risk factor for herpes zoster in children: a population-based cohort study","volume":"49","author":"Chen","year":"2017","journal-title":"Ann Med"},{"key":"2024102103310565000_64.2.2400462.53","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw205"},{"key":"2024102103310565000_64.2.2400462.54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database","volume":"38","author":"Cutroneo","year":"2024","journal-title":"BioDrugs"},{"key":"2024102103310565000_64.2.2400462.55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9053"},{"key":"2024102103310565000_64.2.2400462.56","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"2024102103310565000_64.2.2400462.57","unstructured":"European Medicines Agency . Shingrix \u2013 summary of product characteristics. 2023. www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf Date last accessed: 12 December 2023."},{"key":"2024102103310565000_64.2.2400462.58","unstructured":"Food and Drug Administration . Shingrix \u2013 package insert. 2023. www.fda.gov\/media\/108597\/download Date last accessed: 12 December 2023."},{"key":"2024102103310565000_64.2.2400462.59","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10\u2005years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024102103310565000_64.2.2400462.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"2024102103310565000_64.2.2400462.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2024102103310565000_64.2.2400462.62","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1627818"},{"key":"2024102103310565000_64.2.2400462.63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","article-title":"Meta-regression of herpes zoster incidence worldwide","volume":"11","author":"Curran","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00462-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:21:08Z","timestamp":1740381668000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00462-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,8]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1183\/13993003.00462-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00462-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}